sorafenib

Org: State Key Laboratory of Biotherapy and Cancer Center, Department of Liver Transplantation Center, Division of Liver Surgery, Laboratory of Liver Surgery, Collaborative Innovation Center of Biotherapy,

Abstract

Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.

Org: H. Lee Moffitt Cancer Center and Research Institute,

Abstract

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,

Abstract

Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.

Org: Saint-Luc University Clinics, Brussels, Belgium, Eugène Marquis Center, Rennes, France, Claude Huriez Hospitals, Lille University Hospital, Lille, France, Ghent University Hospital, Ghent, Belgium, CR UK Liverpool Experimental Cancer Medicine Centre and Clatterbridge Cancer Centre, Liverpool, United Kingdom,

Abstract

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

Org: Taipei, Taiwan, Sutter/California Pacific Medical Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China, Ibaraki, Japan,

Abstract

RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.

Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,

Abstract

SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.

Org: Department of Hepatobiliary Pancreatic and Splenic Surgery, Baoji Central Hospital, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, The First Affiliated Hospital of Bengbu Medical University,

Abstract

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Org: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, Chinese University of Hong Kong, Hong Kong, China, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China, Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China, Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Department of General Surgery, Anhui Provincial Hospital, Hefei, China, Department of Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Center, Guangzhou, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation, Department of Infectious Disease and Hepatology, Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, Poland, Department of Liver and Pancreas Gland Oncosurgery, Communal Non-profit Enterprise "Regional Center of Oncology", Kharkiv, Ukraine, Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, China, National Taiwan University Hospital, Taipei, Taiwan, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, Cancer Center of Nanjing, Jinling Hospital, Nanjing, China,

Abstract

Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.

Org: Weill Medical College at Cornell University,

Abstract

Anti-angiogenic TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis.

Org: Universidade Estadual do Centro Oeste (UNICENTRO), Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Emily Couric Clinical Cancer Center, University of Virginia,

Abstract

Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,

Abstract

Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.

Org: Hong Kong Cancer Institute,

Abstract

Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC).

Org: Institute of Liver Studies, Kinomica Limited,

Abstract

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

Abstract

Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.

Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,

Abstract

Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study.

Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital,

Abstract

Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.

Org: Saint Mary's and Saint Clare's Hospital, Howard University Hospital, Reg Cancer Center at St Michael's Medical Center, St. Michael's Medical Ctr,

Abstract

Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.

Org: PLA General Hospital,

Abstract

The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients.

Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico,

Abstract

The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,

Abstract

Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.

Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Clinical trial

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Status: Recruiting, Estimated PCD: 2030-09-01

Clinical trial

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Status: Active (not recruiting), Estimated PCD: 2015-08-01

Clinical trial

Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Status: Completed, Estimated PCD: 2020-12-30

Abstract

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

Org: Humanity and Health Clinical Trial Center, Liver Unit and HPB Oncology Area, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Barcelona Clinic Liver Cancer,

Abstract

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.

Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, University of Texas Southwestern Medical Center, Division of Digestive and Liver Diseases, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.

Org: Sutter/California Pacific Medical Center, Marqués de Valdecilla University Hospital, IDIVAL, The Chinese University of Hong Kong, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,

Abstract

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Org: City of Hope Comprehensive Cancer Center, Roche (China) Holding Ltd., Asan Medical Center, Genentech, Roche Products Ltd.,

Abstract

Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the KEYNOTE-394 study.

Org: MSD China, Merck & Co., Inc.,

Abstract

NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.

Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute,

Abstract

Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.

Org: BeiGene (Ridgefield Park) Co., Ltd., BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Co., Ltd.,

Abstract

Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.

Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,

Abstract

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,

Abstract

Comprehensive CRISPR-enabled functional genomics profiling to identify targetable cancer genes in primary acute myeloid leukemia (AML).

Org: Function Oncology, San Diego State University Department of Biology, San Diego, CA, Cambridge University Hospitals NHS Foundation Trust,

Abstract

Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

Org: Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Rogel Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Bashkir State Medical University,

Abstract

Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.

Org: The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of China Medical University,

Abstract

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Org: BeiGene (USA) Co., Ltd., BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Co., Ltd., Jiahui Cancer Center, Massachusetts General Hospital,

Abstract

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China National Biotec Group, Shandong Suncadia Medicine,

Abstract

The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.

Org: Gastrointestinal Medical Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan, Department of Nursing and Health Promotion, Group of Supportive Care and Survivorship Research, Institute for Cancer Control,

Abstract

Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma.

Org: Capital Medical University, Department of Human Cell Biology and Genetics, Southern University of Science and Technology School of Medicine, Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital,

Abstract

The analysis of BRAF fusions characteristics in Chinese solid tumor patients.

Org: The Second Xiangya Hospital of Central South University, Nanjing Simcere Medical Laboratory Science Co., Ltd.,

Abstract

Genomic and transcriptomic profiling of inflammatory breast cancers and non-inflammatory breast cancers in Asian women.

Org: Breast Disease Center, West China Hospital, Sichuan University, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China,

Abstract

Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study.

Org: University of Texas MD Anderson Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics, Roswell Park Cancer Institute, University of Michigan Medicine, Einstein Healthcare Network,

Abstract

Efficacy and safety in unresectable hepatocellular carcinoma with VP4 tumor embolus using sinilimab plus bevacizumab: A retrospective analysis of real-world evidence.

Org: Senior Department of Hepatology, 5th Medical Center of the PLA General Hospital, Peking University 302 Clinical Medical School, The Fifth School of Clinical Medicine, Anhui Medical University,

Abstract

PVR expression in tumor microenvironment of advanced hepatocellular carcinoma.

Org: National Taiwan University Hospital Yunlin Branch, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Cancer Center/Hospital,

Abstract

Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,

Abstract

Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A systematic review and network meta-analysis.

Org: Chinese Academy of Sciences, Zhejiang Chinese Medical University,

Abstract

Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members.

Org: Ohio State University Comprehensive Canvcer Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, James Thoracic Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network.

Org: Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea, IQVIA Solutions Korea Ltd, Seoul, South Korea, IQVIA Solutions Asia Pte Ltd, Singapore, Singapore,

Abstract

Efficacy of low dose sorafenib and capecitabine in the management of hepatocellular cancer.

Org: Department of Radiotherapy and Oncology, University Hospital Center Osijek, MINAR Cancer Hospital, Multan Cancer Hospital,

Abstract

Portal hemodynamic effects of different TKIs in patients with advanced hepatocellular carcinoma: A prospective cohort study.

Org: Comprehensive HCC Center, The Fifth Medical Center of the PLA General Hospital, Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital,

Abstract

Risk factors, clinical characteristics, and treatment outcomes for hepatocellular carcinoma in Rwanda.

Org: University of Illinois at Chicago College of Medicine, Division of Medical Oncology, University of Rwanda, College of Medicine and Health Sciences, United Arab Emirates University, Alain, United Arab Emirates, King Faisal Hospital (KFH), University Teaching Hospital of Kigali (CHUK),

Abstract

Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma.

Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Department of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Shanghai Hongkou Center for Disease Control and Prevention, Shanghai, China, Department of Vascular Surgery, Changzheng Hospital, the Naval Medical University, Shanghai, China, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China,

Abstract

Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.

Org: Department of Liver Surgery & Transplantation Center, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China, Zhongshan Hospital Liver Cancer Institute, Shanghai, China, Department of Pathology，Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China,

Abstract

Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.

Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,

Abstract

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.

Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,

Abstract

Examining the treatment journey of patients diagnosed with hepatocellular carcinoma (HCC) using retrospective real-world data in British Columbia, Canada.

Org: Sunnybrook Research Institute, BMZ Analytics, BC Cancer Agency Vancouver Island Centre, University of British Columbia, British Columbia Cancer Agency,

Abstract

Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.

Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,

Abstract

Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.

Org: Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU Health Shreveport, Ochsner LSU Health, Merit health, LSUHSC-S,

Abstract

Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study.

Org: The Fifth Medical Center of the PLA General Hospital, The Fifth Medical Center of Chinese PLA General Hospital,

Abstract

Therapeutic outcomes of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Org: University of Texas MD Anderson Cancer Center, Houston, TX, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, JCCR, Varanasi, India, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo University, Cairo, Egypt,

Abstract

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.

Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,

Abstract

OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3.

Org: Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China, West China Hospital, Sichuan University,

Abstract

Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.

Org: Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.

Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University,

Abstract

Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.

Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,

Abstract

Regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma efficacy and safety of patients: A real-world study.

Org: Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China, Department of Hepatobiliary and Pancreatic Surgery, Tianjin First Central Hospital，Nankai University, Tianjin, China, Nankai University, Tianjin, China, Tianjin medical University, Tianjin, China,

Product

Sorafenib

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10245